Search Results

You are looking at 1 - 10 of 85 items for :

  • "second-line chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Management of Recurrent Small Cell Lung Cancer

Bryan J. Schneider

irinotecan in refractory small cell lung cancer] . Gan to Kgaku Ryoho 1995 ; 22 : 889 – 893 [in Japanese] . 20. Nakanishi Y Takayama K Takano K . Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung

Full access

Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All?

Presented by: Andrew D. Zelenetz

standard of care for chemosensitive relapse, Dr. Zelenetz said. However, he noted that this therapy may also have a role in treatment for patients with only a partial response after second-line chemotherapy. A study of the CIBMTR registry evaluated

Full access

Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Jane N. Winter, Joachim Yahalom, and Hema Sundar

after HDT/ASCR compared with those with resistant disease. 32 , 33 Moskowitz et al. 32 reported that the EFS, PFS, and overall survival rates were significantly better for patients responding to second-line chemotherapy (60%, 62%, and 66%, respectively

Full access


. The Panel revised the related footnote to read, “Randomized clinical trials in metastatic breast cancer document that the addition of bevacizumab to some first or second line chemotherapy agents modestly improves time to progression and response rates

Full access

Targeted Therapy in Relapsed Classical Hodgkin Lymphoma

Shira Dinner and Ranjana Advani

Although frontline treatment of advanced Hodgkin lymphoma (HL) produces high cure rates, disease either will not respond to or will relapse after initial therapy in approximately a quarter of patients. Many patients with disease relapse can be successfully salvaged with second-line chemotherapy followed by autologous stem cell transplantation (ASCT). Patients whose disease relapses after ASCT are rarely cured. A unique pathophysiologic feature of HL is that the malignant Reed-Sternberg (HRS) cell is rare and resides within a microenvironment of inflammatory and immune-related cells. The recent FDA approval of the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) for patients with either primary refractory HL or those whose disease relapses after ASCT represents a major advance in therapy. This article focuses on BV and other novel agents that target the HRS cell surface, intracellular signaling pathways, and tumor microenvironment.

Full access

Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab

Katherine Cotangco, Mary Meram, and M. Patrick Lowe

The estimated 5-year survival rate for patients with stage IV uterine leiomyosarcoma is 29%, with a median survival of <1 year. This report describes a patient with stage IVB leiomyosarcoma who experienced stable disease for 15 months on pembrolizumab. A woman aged 62 years, gravida 2 para 2, with postmenopausal bleeding and a necrotic uterine fibroid underwent a dilation and curettage and was diagnosed with uterine leiomyosarcoma. CT imaging showed pulmonary and bony metastasis. She underwent surgical staging with biopsy-proved stage IVB disease. A mixed partial response was noted using first- and second-line chemotherapy. Molecular tumor profiling confirmed PD-L1 expression. The patient was started on pembrolizumab, and at the time of writing she is status post 23 cycles with stable disease. Pembrolizumab was well tolerated and aided prolonged disease stabilization.

Full access


percentage of patients are not able to be treated with second-line therapy at disease progression if a strategy of “watchful waiting” is chosen? No population-based data are available on the rates of second-line chemotherapy in patients with documented

Full access

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

2017–2018. In general, of the 1,586 patients who received first-line systemic therapy, 419 died and 339 did not die within 90 days of stopping treatment. Of the patients who died within 90 days, only 4% received second-line chemotherapy, and of the

Full access

Treatment of Advanced Soft Tissue Sarcoma: Conventional Agents and Promising New Drugs

Andrew Wagner

: 1537 – 1545 . 3. Verweij J Lee SM Ruka W . Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European

Full access

Role of New Chemotherapy Agents in Soft Tissue Sarcoma

Margaret von Mehren

Sandler A Blessing J . Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study . Gynecol Oncol 2004 ; 92 : 644 – 647 . 6 Hensley M Maki R Venkatraman E . Gemcitabine and